|Description||Fedratinib is a potent and selective JAK2 inhibitor with IC50 value of 6 nM. It also exhibits inhibitory effects against FLT3 (IC50 = 25 nM), RET (IC50 = 17 nM) and JAK3 (IC50 = 169 nM).|
|B0084-100796||25 mg||$198||In stock|
|B0084-100796||50 mg||$298||In stock|
|Synonyms||TG101348; SAR302503; N-tert-butyl-3-[[5-methyl-2-[4-(2-pyrrolidin-1-ylethoxy)anilino]pyrimidin-4-yl]amino]benzenesulfonamide|
TG101209 is a novel and potent JAK2 inhibitor. The induction of cytotoxicity was associated with inhibition of cell cycle progression and induction of apoptosi...
Peficitinib, also known as ASP015K and JNJ-54781532, is a novel potent JAK inhibitor, which demonstrated potent efficacy in adjuvant-induced arthritis model in ...
Tofacitinib (CP-690550,Tasocitinib) is a novel inhibitor of JAK3 with IC50 of 1 nM, 20- to 100-fold less potent against JAK2 and JAK1.It is currently approved f...
ZM 39923 hydrochloride
ZM 39923 hydrochloride is a potent and selective inhibitor of Janus tyrosine kinase 3 (JAK3) (pIC50 = 7.1, 5.6, 4.4, and < 5.0 for JAK3, EGFR, JAK1 and CDK4, re...
NS-018, a selective JAK2 as well as Src family tyrosine kinases inhibitor that could probably induce the apoptosis of tumor cells. It is still under Phase I/II ...
JAK2 Inhibitor IV
JAK2 Inhibitor IV is a potent and selective Janus Kinase 2 (JAK2) inhibitor that inhibits the activity of both the wild-type JAK2 and the V617F mutant (IC50 = 7...
Cyt387, also called Momelotinib, under the IUPAC name N-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamide, is an ATP competitive inhib...
Itacitinib is a potent Janus kinase-1 inhibitor under the development of AstraZeneca and Incyte Corporation. Itacitinib can inhibit OCT2-mediated uptake of crea...
SD 1008 is a JAK2/STAT3 signaling pathway inhibitor that inhibits activation of STAT3, JAK2 and Src. SD 1008 induces apoptosis in cell lines expressing constitu...
ZM 39923 HCl
Selective inhibitor of Janus tyrosine kinase 3 (JAK3). pIC50 values are 7.1, 5.6, 4.4, and < 5.0 for JAK3, EGFR, JAK1 and CDK4 respectively. Breaks down in neut...
Oclacitinib maleate was the first selective Janus kinase (JAK) inhibitor to be developed for dogs. Oclacitinib is most potent at inhibiting JAK1 (IC50=10 nM).
Solcitinib, also known as GSK2586184 or GLPG0778, is a Janus kinase 1 (JAK1) inhibitor. Solcitinib may be potential useful for treatment of psoriasis, systemic ...
Atiprimod dihydrochloride is the dihydrochloride salt form of atiprimod, which is an orally bioavailable small molecule belonging to the azaspirane class of cat...
Oclacitinib, also known as PF03394197, is a novel Janus kinase inhibitor with activity against cytokines involved in allergy. Oclacitinib inhibited JAK family m...
In cell lines, GLPG0634 inhibits IL-2- and IL-4-induced JAK1/JAK3/γc signaling and IFN-αB2-induced JAK1/TYK2 type II receptor signaling with IC50 ranged from 15...
NSC-33994 is a selective inhibitor of JAK2 with IC50 of 60 nM.
This active molecular is a novel Janus Kinase 3 (JAK3) inhibitor. CP-690550A is an immunosuppressant for the treatment of rheumatoid arthritis, psoriasis, trans...
WHI-P97 is a potent cell-permeable and specific inhibitor of JAK3(IC50 = 11 μM). Inhibits JAK3 in immune complex kinase assaysin a dose-dependent fashion and re...
Fedratinib is a potent and selective JAK2 inhibitor with IC50 value of 6 nM. It also exhibits inhibitory effects against FLT3 (IC50 = 25 nM), RET (IC50 = 17 nM)...
WHI-P154 is a JAK3 inhibitor with IC50 = 1.8 μM. WHI-P154 displays no activity at JAK1 or JAK2. WHI-P154 also Inhibits STAT1 activation, iNOS expression and N...